Revenue

In a recent announcement, the Food and Drug Administration granted approval for Moderna’s vaccine for respiratory syncytial virus (RSV) for adults aged 60 and older. This marks a significant milestone for Moderna, as it diversifies its product portfolio beyond its Covid jab, which has seen a decrease in demand. The decision to approve Moderna’s RSV
0 Comments
The Municipal Bond market experienced a surge in issuance in May, surpassing $40 billion for the first time since 2016. The current volume of $43.957 billion in 866 issues represents a significant increase of 46.9% from the previous year. This surge in issuance can be attributed to several factors, including Federal Reserve policy uncertainty, pent-up
0 Comments
Baird recently initiated UnitedHealth as outperform, citing the health insurance company as a favorite idea at the firm. The firm views UnitedHealth Group as the most vertically and horizontally integrated Managed Care company, with a $597 price target indicating a potential 20% upside. Evercore ISI upgraded Okta to outperform from in line after the identity
0 Comments
American Airlines recently announced a significant reduction in its sales forecast, leading to concerns about the company’s financial health. The airline also made the decision to part ways with its chief commercial officer, Vasu Raja, who is set to depart from his position next month. This series of events has raised red flags among investors
0 Comments
Morgan Stanley’s recent updated forecasts suggest that Tuya, a U.S.-listed Chinese company that generates most of its revenue internationally, has the potential to see a significant increase in its stock price. Analysts have increased their price target for Tuya and expect the company’s shares to rise in the short term due to its recent financial
0 Comments
The idea of a nuclear renaissance has been circulating for years, with promises that have failed to materialize in the past. However, recent signals suggest that this time around, the hype may actually be legitimate, according to analysts at Morgan Stanley. The firm highlights Curtiss-Wright as a potential standout in the nuclear industry, with a
0 Comments